Funding
← Back to your selection

Thrive Capital

Activity from announced rounds

Activity in this selectionOct 25, 2026 · Biotech · Jan 1, 2026

Thrive Capital builds and invests in internet, software and technology-enabled companies, combining an investment business with company incubation.

Thrive Incubations works with founders through idea exploration, product development and company launch. It is a route for entrepreneurs building a business from the beginning, alongside Thrive’s investments in existing companies.

Sources
Rounds participated in
3
Confirmed lead rounds
0
2 roles undisclosed
New companies
3
First participation on record · 0 follow-on
Funding in participating rounds
$2.9B
3 disclosed · full round size, not this investor’s share

By stage

Series C+2
Series B1

By primary sector

Biotech3

By country

United States2
United Kingdom1

Rounds

3 in this selection
Chai Discovery

Building AI models to accelerate pre-clinical drug discovery

$400MSeries C
Role not disclosed
NewLimit

NewLimit develops epigenetic reprogramming medicines designed to restore function in aging cells and treat age-related disease.

$435MSeries C
Participant
Isomorphic Labs

Builds an AI-first drug design engine to accelerate discovery and development across multiple therapeutic areas

$2.1BSeries B
Role not disclosed